CardiologyOnline.net

Cardiology Xagena

Search results for "Rivaroxaban"

The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant Rivaroxaban ( Xarelto ) demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thrombo ...


Initial results from a phase 2 proof-of-concept study of Andexanet alfa, investigational factor Xa inhibitor antidote, in healthy volunteers who were administered the factor Xa inhibitor Rivaroxaban ( ...


The oral anticoagulant Xarelto ( Rivaroxaban ) has been approved by the European Commission for the prevention of atherothrombotic events ( cardiovascular death, myocardial infarction or stroke ) afte ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Xarelto ( Riva ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa ( Dabigat ...


The European Committee for Medicinal Products for Human Use ( CHMP ) has recommended approval of oral anticoagulant Xarelto ( Rivaroxaban ) 2.5 mg twice-daily in combination with standard antiplatelet ...


Anticoagulant treatment with vitamin K antagonists ( VKAs ) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation ...


For patients with atrial fibrillation or atrial flutter of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown, anticoagulation with Warfarin ( INR 2.0 to 3.0 ) is recom ...


Antiarrhythmic drugs ( AADs ) and anticoagulation are mainstays of atrial fibrillation ( AF ) treatment. A study has assessed the use and outcomes of antiarrhythmic therapy in anticoagulated patients ...


European Xarelto ( Rivaroxaban ) product information has now included guidance for use in patients with atrial fibrillation undergoing cardioversion. The label update is based on findings from the ...


With the introduction of novel oral anticoagulants ( NOACs ), the factors driving anticoagulant selection in atrial fibrillation ( AF ) in real-world practice are unclear. The goal was to examine ...


Oral anticoagulant therapy with Rivaroxaban ( Xarelto ) is a safe alternative to Vitamin K antagonist ( VKA ) therapy in patients with atrial fibrillation who are undergoing elective cardioversion to ...


X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. Researchers have assigned 1504 patients to Riv ...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis ) show similar efficacy for stroke prevention in patients with atrial fibrillati ...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial fibrillation ( NVAF ) w ...